title: Arrowhead Pharmaceuticals
id: 49000608
Arrowhead Pharmaceuticals is a publicly traded biopharmaceutical company based in Pasadena California Arrowhead s products in development act through RNA interference RNAi mechanisms of action The company focuses on treatments for hepatitis B liver disease associated with alpha antitrypsin deficiency and cardiovascular disease The company has sixteen products in its pipeline in various stages of development br br In the company substantially expanded its intellectual property holdings through complete acquisition of the full RNAi research and development portfolio and assets from Novartis br In April it was announced that the former company name Arrowhead Research Corporation will be changed to Arrowhead Pharmaceuticals Inc br In September Arrowhead entered into two collaboration and licensing agreements with Amgen Under the deals Amgen received a worldwide exclusive license to Arrowhead s ARO LPA RNAi program and an option to a worldwide exclusive license for ARO AMG both for cardiovascular disease br On Oct Arrowhead Pharmaceuticals Inc closed on a billion license and collaboration agreement with Janssen to develop and commercialize ARO HBV As part of the deal Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference RNAi therapeutics against new targets to be selected by Janssen br br br 